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ABSTRACT
The negative health impact of chiral environmental pollutants (CEPs), including mutagenicity,
teratogenicity, and developmental problems, highlight the importance of chirality to the
biomedical research community and the need for new techniques for accurate analysis of CEPs
in humans to promote the development of biomedical protocols for CEPs poisoning therapy. This
study examined the effects of chirality on 1-(9-anthryl)-2,2,2-triflouroethanol (TFE) and
1,1′binaphthyl-2,2′-diamine (BNA) enantiomers interactions with human serum albumin (HSA),
the dominant serum protein and a transporter of hormones, drugs and metabolites in human.
Specifically, the emission, the binding constants, stoichiometry, and thermodynamic properties
of enantiomers of TFE-HSA and BNA-HSA complexes were investigated using analytical
spectroscopy (Fourier transform infrared, UV-visible and fluorescence). The influence of
experimental conditions such as the temperature and the concentration of TFE and BNA
enantiomers on TFE-HSA and BNA-HSA complexations were also investigated. In addition, the
effect of TFE and BNA enantiomers on the mobility of HSA in solution was explored by the use
of steady state fluorescence anisotropy measurement. Furthermore, enantiomeric cytotoxicity
and cell viability of TFE and BNA enantiomers on triple negative breast cancer cells was
investigated. The results of this study showed considerable differences in the emission property,
the binding constants, and thermodynamic properties of the enantiomers TFE-HSA and BNAHSA complexes, indicating diastereomeric complex formations and chiral discrimination. The
result of the study also showed differences in the TFE and BNA enantiomeric cell cytotoxicity
and cell viability on triple negative breast cancer cells.
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CHAPTER 1
INTRODUCTION
1.1 Chirality
1.1.1 Background
The developments of stereochemistry and molecular chirality can be dedicated to the
work of French scientists Jean Biot and Louis Pasteur over 190 years ago.1,2 Biot was the first to
report on chirality of a molecule and paved the way for Louis Pasteur. Pasteur began his
investigations on crystallography of tartaric acid (TA) and at the young age of twenty-five, he
later gave his memoir on the discovery to the Academy of Sciences in Paris in 1848. Pasteur
noted that from his crystal cleavage observations, a crystal of each constituent space filling
molecule are images of each other in overall shape. Below is Pasteur original drawing of the two
crystals.

Figure 1. Pasteur’s Original Drawing of TA Crystal structure 2
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Although the term chirality was not used until 1894 by Sir William Thomas, chirality is
said to be derived from the Greek word “kheir” meaning hand. Chirality is now formally defined
as the geometric property of an object of not being superimposable with its mirror image.2
Simplistically, chirality refers to spatial arrangement but more specifically, it explains the ability
of a molecule to exist in two or more forms but neither form is able to be superimposed on its
mirror image. A chiral molecule is therefore said to not have a plane of symmetry (Figure 3), not
have an inversion center, have a non-superimposed mirror image and have at least one chiral
center (Figure 2).When a molecule can be superimposed on its mirror image it is said to be
achiral (the opposite of chiral).

HO

CF 3

A

HO

CF 3

B

Figure 2. (S)-(+)-1-(9-Anthryl)-2,2,2-trifluoroethanol and (R)-(−)-1-(9-Anthryl)-2,2,2trifluoroethanol
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A

B

Figure 3. (R)-(+)-1,1′-binaphthyl-2,2′-diamine and (S)-(-)-1,1′-binaphthyl-2,2′-diamine

In 1874, Jacobus Henricus Van't Hoff and Joseph Le Bel reported that the tetrahedral
arrangement of the carbon that were bound to different groups in ammonium tartrate made the
entire molecule asymmetric in structure. The resulting carbon atom is said to be the asymmetric
or the chiral center.3

1.1.2 The Language of Chirality
Pasteur gave birth to the oldest terminology in molecular chirality. He gave the name
dissymmetry to describe this phenomenon of left and right handedness in molecules. Over the
next 50 plus years the evolution in terminology of molecular chirality was contributed to many
scientist. In 1874, Jacobus Henricus Van’t Hoff discovered what he called the asymmetric
carbon atom. In 1886 the German chemist Aemilius Wunderlich introduced configuration and, in
1889 German chemist, Viktor Meyer coined stereochemistry. The terms chirality and chiral were
introduced in 1894 by the British physicist Sir William Thomson while the base word “enantio”
used in words such as enantiomer, enantiomorph and enantioselective was introduced in 1856 by
the German crystallographer Carl Friedrich Naumann.2
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Enantiomer is the term used to describe chiral molecules with noon superimposable
mirror images. After Pasteur’s manual separation of the two tartaric acid crystals, he observed
that linearly polarized light was affected differently by the enantiomers. He found the rotations to
be equal in absolute magnitude but opposite in their direction. This observation of light led to the
D/L convention method of naming enantiomers. When polarized light interacts with an
enantiomer it undergoes an optical rotation. If an enantiomer rotates the light to the right it is
termed dextro- rotary and denoted with a + sign.4 If the enantiomer rotates the light to the left it
is termed levo-rotary and denoted with a – sign. A racemic mixture is indicated by a (±) sign
meaning there is a 1:1 enantiomer mixture. In order for scientist to understand the absolute
configuration of the molecule, another naming system was established, the R/S system. Once the
structure has been determined the substituting atoms that are bound to the chiral carbon are
numbered in order of priority with respect to their atomic number. The higher atomic number
gaining the highest priority. The molecule is then viewed opposite to the lowest group and if the
order of the groups are in a clockwise direction it’s assigned the R configuration. If the order of
the groups are in a counter clockwise direction it’s assigned the S configuration.

Figure 4. Depiction of R/S Naming Configuration

6

1.1.3 Chirality in Drug Design
The phenomenon of chirality discovered in 1984 has now developed into its own sub
discipline of chemistry known as stereochemistry where the study of spatial arrangement of
atoms in a molecule and their manipulation is analyzed. Pasteur’s contributions to chirality did
not end with stereochemistry. After his research shifted Pasture discovered biological
enantioselectivity in 1857 when he noticed that the enantiomers of TA were being metabolized at
different rates by the same microorganism. It wasn’t until 30 years later that the first report on
enantioselectivity at a biological receptor was made. Italian scientist Arnaldo Piutti was
responsible for this noted phenomenon back in 1886. A receptor is a molecule that can receive
chemical signals coming from outside of the cell. Piutti’s discovery of enantioselectivity was due
to the taste of asparagine. Piutti noticed there was a difference in taste between the pure Dasparagine (sweet taste) and the L-asparagine (tasteless). This was the first indication of a
biological receptor (sweet receptor) showing enantioselectivity.

O

NH2

NH2

OH

HO

H2N

NH2

O

L - Asparagine

O

O

D - Asparagine

Figure 5. D- and L- Asparagine
Centuries later Piutt’s discovery still is of great interest when it comes to the chemical
and biological aspects of molecular chirality. Molecular chirality plays a huge importance in
pharmacotherapy and the development of new drugs primarily because chiral molecules are the
major ingredient to many therapeutic agents. In 1987 a Swedish manual of drugs in clinical use
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were surveyed and 53% were said to have contained a minimum of one stereogenic center and
out of that 53% that contain a chiral carbon 49% were racemic and 51% were in use as single
enantiomeric form.2,5
As Piutt demonstrated enantiomers possess identical, physical and chemical properties.
However in the presence of other chiral systems these properties can be significantly different.
The proteins that make up our biological system are large complex chiral molecules resulting in
the significance chirality plays in drug design and development. The process of drug action or
delivery requires a chemical interaction between the enantiomer of a drug and a biological
receptor. The bonding interactions between a drug and a receptor is dependent on functionalities
associated with the drug and the binding sites on the receptor. In the case of enantiomers, spatial
arrangement is one of these dependent functionalities. An example of the significance of spatial
arrangement is illustrated below.

Figure 6. Schematic Representation of Enantiomers of a Chiral Molecule Receptor6

The ability of one enantiomer to “fit” into the binding site of a receptor may not produce
identical binding energy or reaction thus resulting in on enantiomer being more favorable or
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having a higher affinity. When two enantiomers of a chiral drug are in the presence of a chiral
receptor (biological system) the difference between the reactions can be beneficial, ineffectual or
even destructive.6
An example would be the Thalidomide episode of 1957 when a German pharmaceutical
company introduced a new drug to the market. The drug was intended to be a sedative to relieve
morning sickness in pregnant woman. This drug contains one chiral center making it a chiral
molecule and the drug was marketed as a racemic mixture. After thousands of children were born
with abnormal body parts and limbs missing scientist discovered that while the (+)(R)thalidomide is a sedative the (-)(S)-thalidomide is a teratogen.7
O

N
H
O

O

O

*

O

*

N
O

(+) (R)-thalidomide

N
H

H

O

N
H
O

(-) (S)-thalidomide

Figure 7. R- and S- Thalidomide

It wasn’t until 1992 when the Federal Drug Association recognized the importance that
chirality play in the development of drug design and began to initiate strict guidelines on chiral
drugs. Pharmaceutical companies are now required to evaluate the toxicity and actions of
enantiomers as two separate drugs.
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1.2 Human Serum Albumin (HSA)
1.2.1 Function of HSA
Human Serum Albumin is one of the most widely noted proteins with research dating
back over 160 years. This large globular protein is synthesized in the liver and accountable for
60 percent of the total proteins found in the human blood.8 Human serum albumin has a
circulating blood concentration of about 6mM. As the most abundant protein, HSA has the
responsibility of maintaining osmotic pressure and being the major transporter of many drugs,
fatty acids, metals and ligands both exogenous and endogenous. The large abundance of HSA is
one of the major reasons why this protein is used to study the pharmacokinetic behavior of many
drugs.9

1.2.2 Structure of HSA
Human serum albumin is a single chained macromolecule that is comprised of 585 amino
acids: Lys59, His16, Arg24, Asp53, Thr28, Ser24, Glu82, Pro24, Gly12, Ala62, Cys35, Val41, Met6, Ile8,
Tyr18, Phe31, and Trp1 which contribute to its total molecular weight of 66.5kDa.9,10
Crystallography studies reveal that this albumin is 67% alpha helix, 10% beta turn, and 23%
extended chain and folded into a heart shaped molecule with an average thickness of 30
angstrom.
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Figure 8. Crystal Structure of Human Serum Albumin6
Human Serum Albumin is formed into three different but structurally similar domains;
Domain 1, 2, and 3. Each has two subdomains denoted as A and B. Structural studies have been
done to help map out binding site specificity.11 There are two reported principle drug binding
sites located in the subdomains A of domain 2 and 3. These sites are known as Sudlow’s Site 1
and 2, respectively. Site 1 is described as being a large hydrophobic cavity with the entrance to
the cavity being surrounded with positively charged residues such as Lys, His and Arg that can
interact electrostatically with ligands while the inside wall is reported to be occupied by
hydrophobic side chains. Typical ligands for this domain are reported to be dicarboxylic acids
and bulky heterocyclic molecules. Literature notes that this site must be large because it has been
reported to bind ligands as large as bilirubin.6 Site 2 is described as a hydrophobic T shaped
cavity with two entrances. Both entrances interact with the carboxylic groups on bound ligands.
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Figure 9. Complete amino acid sequence of HSA10
1.2.3 HSA Intrinsic Fluorescence
Human serum albumin contains three aromatic amino acid residues that can lead to its
natural fluorescence (tryptophan, tyrosine, and phenylalanine). Each of the three residue have
distinct absorption and emission wavelength and differ significantly in their quantum yields and
lifetimes. Tryptophan residues emit a much stronger fluorescence and has a higher quantum yield
in comparison to tyrosine and phenylalanine. Typical absorption and fluorescence values are
shown in a chart below. The intensity, quantum yield, maximum fluorescence and wavelength of
tryptophan residues are solvent dependent. When the tryptophan residue is in the presence of a
polar solvent the fluorescence shifts to shorter wavelength while inversely the fluorescence
intensity increases. Tryptophan residues that are reported to be buried in hydrophobic cavities
have shifted spectra as opposed to residues found on a proteins surface.
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Table 1.
Absorption and Fluorescence parameters of intrinsic amino acids
Absorption
Wavelength
(nm)

Lifetime

Fluorescence
Molar
Absorptivity
−1

Wavelength Quantum
(nm)

−1)

(M cm

(ns)
Tryptophan

2.6

280

5600

348

.20

Tyrosine

3.6

274

1400

303

.14

Phenylalanine

6.4

257

200

282

.04

The lone tryptophan residue located in Sudlow’s site 1 of the protein is responsible for its
intense fluorescent emission shifted to 334nm. Tryptophan is an amino acid, aromatic in
structure which makes it highly fluorescent. With many natural biological species containing
tryptophan its change in fluorescence can be used to study protein folding, binding to substrates
and its overall structure.

1.3 Chiral Molecules of Interest
1.3.1 Polycyclic Aromatic Hydrocarbons (PAH)
Polycyclic aromatic hydrocarbons are fused aromatic rings arranged in various isomeric
configurations and are their own class environmental contaminants. Polycyclic aromatic
hydrocarbons are in fact the largest class known for their mutagenic and carcinogenic behavior.
PAH’s occur in the environment predominantly from the incomplete combustion of organic
substances. Many environmental sources of PAH’s include air pollution from industrial sites,
motor vehicle air pollution, smoke from cigarettes and our diet. Humans can be exposed to
PAH’s through skin contact, breathing in air, eating or drinking of contaminated food or water.
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Unfortunately human exposure to even nanogram quantities of PAHs on a daily basis is
unpreventable due to its large abundance in the environment.
The ubiquity of PAH’s were made evident by their detection in sediments, air, soil,
surface waters, drinking water, industrial effluents, plant and animal tissues. PAH’S are
comprised of two or more fused aromatic rings consisting of hydrogen and carbon atoms in
linear, angular or cluster arrangements. Some PAH’s may have substituents attached to one or
more rings. The PAH’s that have substituents may sometimes exhibit greater toxicological
effects than the parent compound. PAH’s with molecular weight ranging from 128.16
(naphthalene) to 300.36 (coronene) are environmental concerns due to their mobility. PAH’s
with high molecular weight are immobile with extremely low volatility and solubility.

1.3.2 Chiral Environmental Pollutants (CEPS)
The health, growth and longevity of the human race and of all other organism depend
heavily on the quality of the environment. Thus, protection and preservation of the environment
is essential and with current industrialization and the increasing developments in the world
pollution is a crucial problem.12 Proper monitoring of these pollutants is both necessary and
important for the health of all populations. Numerous reports have been published indicating
how chiral environmental pollutants can cause harmful effects to the human reproductive system.
Among various environmental pollutants, PAH’s are the most toxic due to their carcinogenic,
teratogenic, and mutagenic nature.13 Some PAH derivatives are chiral toxic pollutants.
Additionally some non-chiral pollutants degrade into the environment and their degradation
products are toxic and chiral in nature.14 There have been reports on the analysis of organic
pollutants but these reports do not distinguish between enantiomers of chiral pollutants as
separate pollutants.
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1.4 Breast Cancer
1.4.1 Background
Cancer is a global disease that has been the result of millions of deaths dating back to the
ancient Egyptian times.15 Cancer is a disease characterized by uncontrollable growth, spread and
accumulation of abnormal cells.15 Abnormal cells can become cancerous when the damage is
done to DNA. The cells are unable to repair the damage and unlike normal cells, the abnormal
cells do not die off. Cancer is always named after the tissue it originates from meaning cancer
may spread to other organs in the body however if it originated in the breast it is still termed
breast cancer. Exceeded only by lung cancer, breast cancer is the second leading cause of cancer
deaths among American women.16 Twelve percent of women in the US will develop breast
cancer in their lifetime and the American Cancer Society estimates that in the following year
there will be 231,840 new cancer cases and of those 40,290 will result in death.16 Breast cancer is
a type of malignant tumor, meaning it has the ability to invade and metastasize to different areas
of the body. Breast cancer is categorized into different stages that depend on the size and
development of the tumor thus treatment options vary depending on the type and stage of the
cancer. Radiation, chemotherapy, hormone therapy and drug-targeted therapy is given to stop the
growth of breast cancer cells. Hormone therapy is used in estrogen (ER), progesterone (PR) and
human epidermal growth factor 2 receptor (HER2) positive cancers. This treatment is used to
stop the growth of cancer cells and is successful for 2 out of 3 breast cancers.

1.4.2 Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is an aggressive type of breast cancer that accounts
for 10-20 percent of the breast cancer cases amongst American women.16 TNBC is PR, ER and
HER2 negative and therefore hormone therapy given to other breast cancer patients is ineffective
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in patients with TNBC. Although TNBC can be detected in all ethnic groups it is more
commonly found in younger African American and Latino women, and women who carry the
BRCA1 mutation. Research has shown that despite TN breast cancer negative response to
hormone therapy, it responds well to chemotherapy in comparison to breast cancer that is
hormone therapy positive.

1.4.3 Cell Viability Assay and Cell Death
Chiral polycyclic aromatic hydrocarbons are found to be very toxic and are impossible to
eliminate from human exposure. It is essential to study the inherent cytotoxicity that may be
associated with these chiral contaminants. Cell viability assays are often used to determine if the
test analyte will have any effects on cell proliferation or show harmful effects that lead to cell
death. Tyrphan blue dye exclusion is widely used to determine the number of viable cells present
in a cell suspension. The mechanism of the dye is based on the theory that cells with an intact
membrane are selective in what they let pass through where as a cells whose membrane is not
intact (dead) will not be selective and uptake the dye. Therefore all the cells that are stained are
considered dead cells. Cells that exclude the dye are viable making tryphan blue a vital stain
allowing discriminator between viable and dead cells.

1.5 Fluorescence Spectroscopy
1.5.1 Fluorescence Theory
Since its first observation in 1565 by Monardes, fluorescence spectroscopy has evolved
into a robust and sensitive analytical tool, finding use in all areas of chemistry ranging from
biological to physical applications.17,18 Photoluminescence falls under a larger umbrella called
luminescence spectroscopy and is named with regard to its mode of luminescence.
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Luminescence involves an electron(s) being promoted from its ground level to a higher energy
level. As the electron(s) returns to its ground level energy is given off in the form of light.
Specifically fluorescence is one of two types of photoluminescence defined as the reemission of
energy in the form of light by a substance that has absorbed outside electromagnetic radiation at
a specific wavelength (usually ultraviolet).19,20 Once G.G. Stokes termed the word
“fluorescence” he identified the difference between fluorescence and phosphorescence by the
duration of emission after excitation of the species. However, there was not a solid distinction
between the two types of photoluminescence (fluorescence and phosphorescence). It was not
until 1929 when Francis Perrin made a sufficient distinction between the two. In the case of
fluorescence spin multiplicity remains while in phosphorescence the spin multiplicity is changed
from a singlet to a doublet or vice versa.19 Figure 1 shows the distinction by the Jablonski
diagram where S0 and S1 represent the ground and first electronic state.

Figure 10. Simplified Jabonski diagram
A substance that is able to absorb light was termed a fluorophore. R. Meyer Stokes noted
that the resulting emission of light is emitted at a longer but equal in magnitude wavelength than
that of its absorption.20 The amount of energy emitted and the wavelength upon emission are
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extensive properties that are specific to the fluorophore and its surrounding. When a fluorophore
is exposed to electromagnetic radiation with a specific wavelength the electrons with
corresponding energy will experience a change to its electronic transitions.21,22 Those electrons
absorb the energy and are promoted to a level of higher energy. This promotion of electrons is
favored when moving from the highest occupied orbital (HOMO) to the lowest unoccupied
orbital (LUMO). The molecules will finally relax to its lowest vibrational level and emit energy
in the form of light. The time from a molecule reaching excited state to relaxing back to its
ground state is called its life time (τ) and is around 10ns for typical fluorophores.23
Absorption of a fluorophore can be used interchangeably with excitation in terms of
fluorescence spectroscopy. Absorption is a term to describe the intake of energy by a florophore.
In a more precise termonolgy absorption occurs when changes in matter are actived by an
oscillating electromagnetic field of a specific frequency. When that frequecy is close to the
frequency associated with the activated electronic dipoles of the matter absorption occurs,
denoting why the excitation and emmission of a florophore is an extensive variable.

1.5.2 Flourescence Quenching
Another observation Stokes made was the reduction of flourescence intensity upon the
addition of NaCl to quinine in 1852.18,23 Quenching as it is now known is any process that causes
reduction in the intensity of flourescence. A quencher is any molecule that is responsible for the
reduction in intesity. Quenching measurement can be a reliable tool to measure the assessibility
of a protein and to examine the binding rates and molar ratios. The majority of the research on
quenching was not observed until later years.24,25
However Robert Boyle noticed a phenomenon he called “self-quenching” or
“concentration-quenching” where he noticed quenching in a molecule due to too many molecules
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of the substance itself.20 Other quenching mehanisms include dynamic quenching (collision
between the fluorescent substance and the quenching agent), static quenching (a complex being
formed between the flourescence substance (FA) and the quenching agent (QA) before excitation
occurs) and resonance energy transfer (energy from an excied state is transferred to another
molecule).21,22

FS + QA ↔ COMPLEX ................................................................................................... Equation 1

Static quenching studies are efficient in determining the binding interactions and
stochiometry between large proteins and smaller molecules. The fluorescence quenching of
proteins can be induced by static or dynamic quenching and can be determined based upon its
quenching constant (kq). Dynamic quenching can only have a maximum kq value of 2.0 x 1010
M-1s-1, where kq is greater then this mechanism is an indication of static quenching.22 Dynamic
quenching constants are determined using the Stern-Volmer equation (Equation 2).26
𝐹0
𝐹

= 1+ KSV[QA] .............................................................................................................. Equation 2

[QA] is the concentration of the quenching agent, F0 and F are the fluorescence
intensities of a fluorphore (in this case the protein) in the absence and presence of a quenching
agent respectively. Ksv is the Stern-Volmer quenching constant where its significance is
dependent upon type of quenching. For dynamic quenching Ksv is related to the lifetime (τ0) and
the bimolecular quenching constant (Kq) of the protein by equation 3.
Ksv = Kqτ0 .................................................................................................................................................................................. Equation 3
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However static quenching is given by the following equation;

[𝐹𝑆−𝑄𝐴]

Ksv = Ka = [𝐹𝑆] [𝑄𝐴] .............................................................................................................................................................. Equation 4

Where FS-QA is the concentration of complex, FS is the concentration of the intrinsic
fluorescence substance and QA is the concentration of the quenching agent. In the case for static
quenching its Ksv value is its binding constant. When smaller molecues bind to large proteins
equivelantly as a result of static quenching a modifed Stern-Volmer equation is used to
determine binding constants and stoichiometry between the protein and the smaller molecule.27
𝐹0 −𝐹

log(

𝐹

) = log Ka + nlog [QA] ...................................................................................... Equation 5

Where F0 is the fluorescence intensity in the absence of a quenching agent and F is the
fluorescence intensity after the addition of our quenching agent. When a plot of log [QA] is
made against the log of the change in fluorescence intensity. Linear regression can be used to
calculate the Ka (binding constant) and the n (molar ratio) between the free and bound molecules.

1.5.3 Spectrofluorometer
Fluorescence studies are examined using a spectrofluorometer. A sample is excited by a
beam of light which then passes through a monochromator which ensures a single wavelength is
chosen. As mentioned earlier fluorescence is the resulting emission after excitation, therfore the
detector is arranged at a 90 degree angle to collect emisson independent from the excitation.
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Figure 11. Schematic representaion of a Fluorescence Spectrophotometer

The resulting emission is analyzed by a sensor and is read out on a computer.
Fluorescence spectroscopy is superior in terms of absorbance based techniques because it can be
measured directly. This leads to its high selectivity and sensitivity. 28

1.6 Fluorescence Anisotropy
Fluorescence anisotropy measurements are effectively used in the biomedical industry.
Anisotropy measurements can be used to obtain information about molecular structure, binding,
size, motion and to recognize chiral selectivity between an analyte and a chiral selector.29,30,31 In
fact, the first fluorescence anisotropy was first used to investigate the binding of small molecules
to proteins in 1953. Fluorescence anisotropy methods are accomplished by applying the
relationship between the polarization of light used to excite a sample and the subsequent
polarized light detected from fluorescence.29 In order to fully understand the theory behind
fluorescence anisotropy a firm understanding of polarized light must be had.
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1.6.1 Polarization
Light is made up of electric and magnetic waves (electromagnetic) that are oscillating in
different directions. When scientist speak of the “polarization” of light it refers specifically to the
electric field. The electric field is oscillating in different directions perpendicular to the direction
of propagation. Polarization of light is the transformation of the electric field in different
directions to a single direction. A Polaroid filter is used to polarize unpolarized light. The filter is
made of a material that can block electromagnetic waves of a particular direction. (Schematic
shown below)

Figure 12. Simplified depiction of a polarized light
When polarized light is used to excite a fluorescence molecule the emission given off is
also polarized. The fluorophores that have absorption transition moments oriented parallel to the
vector of the polarized light will be excited leading to the excited population to be partially
oriented.32

1.6.2 Steady State Anisotropy Measurements
Steady state fluorescence anisotropy measurements are calculated by the following equation:
𝐼 −𝐼

r = 𝐼 𝑣𝑣+2𝐼𝑣ℎ ........................................................................................................................ Equation 6
𝑣𝑣

𝑣ℎ

22

Where Ivv and Ivh is the intensity of vertical polarized light and horizontally polarized
light when excited by vertically polarized light respectively. Figure 13 is a schematic diagram for
L- shaped anisotropy measurements. The sample is excited with vertically polarized light while
the electric vector of the excitation light is aligned parallel to the z-axis. A separate polarizer is
placed to measure the intensity of the emission. When this polarizer is aligned parallel to that of
the excitation emission the intensity is called Ivv. When this polarizer is aligned perpendicular to
that of the excitation emission the intensity is called Ivh.33,34

Figure 13. Schematic representaion of Fluorescence Anisotropy Experiment Measurements

When incorporating polarized light with a fluorimeter there may be variations in the
transmission of vertical and horizontal emissions due to sensitivity of detection systems.31 This
error can be accounted for by producing G which is the instrumental correction factor. The G
factor as it is known is the ratio of vertically polarized light to horizontally polarized light using
horizontally excited polarized light.30
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𝐼

G = 𝐼 ℎ𝑣 .............................................................................................................................. Equation 7
ℎℎ

The G factor accounts for the deficiencies in optical measurements thus this factor is
dependent on the slits, filters and wavelengths used.34 Assuming the experimental conditions
remain unchanged, the G factor need only be calculated once. After the incorporation of the G
factor the final anisotropy equation comes out to be as followed;
𝐼 −𝐺𝐼

r = 𝐼 𝑣𝑣+𝐺2𝐼𝑣ℎ ...................................................................................................................... Equation 8
𝑣𝑣

𝑣ℎ

Based off the final anisotropy equation, the values of anisotropy can range from are 0 to
1. The smaller anisotropy value corresponds to faster motion while higher values correspond to
slower motion.

1.6.3 Depolarization
Rotational diffusion is the main cause of depolarization in fluid environments and causes
changes in the direction of the transition moments.30 Fluorescence anisotropy measurements
unveil the angular displacement of the fluorophore from time of absorption to subsequent
emission. With fluorescence anisotropy being dependent on fluorophores motions these
measurements have been widely used for clinical chemistry, to quantify protein denaturation and
to measure the dynamics of proteins.29 Those fluorophores excited have the ability to rotate in
different directions causing a decrease in polarization emission.32
When a large molecule becomes bound to a smaller molecule the change in rotation is the
main cause of fluorescence depolarization while in its excited state. Thus a measurement of
fluorescence polarization can be used to diagnose the mobility of our fluorophore bound and
unbound. Fluorescence anisotropy is a simple one step method for binding assays because it can
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be performed directly and theoretically once there is a change in molecular weight sequentially
there will be a change in anisotropy. 30

1.7 Infrared Spectroscopy
1.7.1 Theory of Infrared Spectroscopy
Infared spectroscopy (IR) is a powerful tool for organic chemist to gather information
pertaining to the structure and for analytical chemist to assess the purity of a compound.35
Infrared spectroscopy utulizes the fact that molecules absorb in the infrared region (between the
visible and microwave region of the electromagnetic spectrum). The IR region can be grouped
into three sub regions: near IR (1400-4000cm-1), mid IR (4000-400cm-1) and far IR (400-10cm1

). The region of our research interest is the mid IR region because this region corresponds to

changes in vibrational energy. Infarared spectroscopy is based on the principle that molecules
have specific frequencies at which they rotate or vibrate in accordance to their vibrational modes.
All nonlinear molecules with N atoms have 3n degree of freedom. Six of which are vibrational.
These vibational modes can absorb infrared energy at different frequencies depending on the
type of bond and the atoms involved. However in order for a vibrational mode in a molecule to
be active it must be associated with changes in the existing dipole moment. For complex
molecules five “normal” vibrational modes exist: rocking, wagging, stretching, scissoring, and
twisting.
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Figure 14. Types of molecular vibrations
1.7.2 Fourier Transform Infrared Spectroscopy
A Fourier transform infrared spectrometer is comprised of moving mirrors, fixed mirrors
and beam splitters. The IR light split into two beams. One is reflected off the fixed mirror while
the other is reflected off the moving mirror. The two beams are reunited at the beam splitter to
produce an interferogram (pattern formed by wave interference). The light from the
interferogram is passed through a sample where some light is absorbed and some light is
transmitted through the sample. The light then reaches the detector and the spectrum is obtained.
Analysis of the transmitted light discloses the amount of energy absorbed at each wavelength.
Infrared spectroscopy is used to obtain information about the chemical bonding and molecular
structure. The spectrum that’s obtained is in essence a molecular fingerprint of the sample taken.
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1.7.3 FTIR for Protein Analysis
FTIR technique has been extensively used to investigate the structure and structural
changes of proteins.25 Contrasting to nuclear magnetic resonance and X-ray crystallography
which gives information about the tertiary structure of proteins, FTIR reveals the secondary
structure of proteins. Bands that are characteristic to all proteins include amide 1 and amide 2.
The amide 1 and 2 bands are a result of carbonyl stretching and N-H bending in peptide bonds.37
This research utilizes FTIR because it has been proven as a powerful tool for studying the
structural changes in proteins due to its high sensitivity, low cost and speed.

1.8 Purpose of Study
It is impossible for the human system to avoid CEPs completely and since most CEPs are
found in the environment as racemic mixtures we are exposed to all enantiomers of that
contaminant. Once CEPs are absorbed into the human body, HSA is its main depot and carrier
protein. Earlier stated enantiomers can have different properties upon interaction thus the
purpose of this study is to distinguish a clear enantiomeric discrimination between (S)-(+)-1-(9Anthryl)-2,2,2-trifluoroethanol and (R)-(-)-1-(9-Anthryl)-2,2,2-trifluoroethanol (a commonly
used enantiomeric solvent for NMR spectroscopy) also (S)-(−)-1,1′-Binaphthyl-2,2′-diamine and
(R)-(+)-1,1′-Binaphthyl-2,2′-diamine (commonly used chiral ligands for transition metal
catalysts) in the presence of HSA. These compounds are ideal in that they are PAH based in
structure but have functional groups that make then chiral in structure. I will also explore the
natural rotation, rotational diffusion upon binding, temporal effects to potentially understand its
mode of binding and the uptake of these contaminants in Triple Negative Breast Cancer cells. It
is hypothesized that there will be a clear bias between binding constants, thermodynamic
parameters and anisotropy measurements between the two enantiomers.
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CHAPTER 2
EXPERIMENTAL METHODS
2.1 Solution Preparation
2.1.1 Materials
All chemicals used were of analytical standard. (R) 1—(9-Anthryl)-2,2,2trifluoroethanol (≥98%, anhydrous), (S) 1—(9-Anthryl)-2,2,2- trifluoroethanol (≥98%,
anhydrous), (R)-(+)-1,1′-binaphthyl-2,2′-diamine (≥98%, anhydrous), (S)-(-)-1,1′-binaphthyl2,2′-diamine (≥98%, anhydrous), Human serum albumin (lyophilized powder, >97%, agarose gel
electrophoresis) and morpholino propanesulfonic acid (MOPS) buffer (BioXtra ≥99.5% titration)
were purchased from Sigma Alderich Chemicals. NaOH electrolytic pellets and Methanol
(≥99.9% anhydrous) were purchased from Fisher Scientific.

2.1.2 Cell Lines
The triple negative breast cancer cells were purchased from American Type Culture
Collection in Manassas, VA. HCC1806 is a basal like cell line that expresses the triple negative
phenotype. Cell line was characterized as a grade 2 tumor derived from a 60 year old African
American woman.

2.1.3 Preparation of Stock Solutions
30mM MOPS buffer solution at pH 7.4 was prepared in a 1 liter volumetric flask by
dissolving 6.27g of MOPS buffer with distilled water and adjusted to pH 7.4 by supplying drop
wise NaOH solution. A .25% stock solution of HSA was prepared by dissolving HSA into a 250mL
volumetric flask and diluted with the previously prepared MOPS buffer solution refrigerated and
allowed to equilibrate for a period of 48 hours. 1.0x10-3M stock solutions of R- and S-TFE were
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prepared by dissolving TFE in 25mL of analytical grade methanol in a volumetric flask. The
1.0x10-3M stock solutions of R- and S-BNA were prepared by dissolving BNA in 25mL of
analytical grade methanol in a volumetric flask. Accurate determination of HSA concentrations
were performed using UV-Visible absorbance with λ max values of 280nm and an extinction
coefficient of 38,553M-1cm-1.

2.1.4 Sample Preparation
Varying amounts of R- and S-TFE and R- and S-BNA were added to a fixed concentration
of HSA in 30mM MOPS buffer solution, pH 7.4. The vials were capped, hand shaken and allowed
to equilibrate for approximately 1 hour to ensure the binding of TFE and BNA to HSA. All samples
were then subject to further analysis. The influence of temperature on the binding and emission
property of TFE-HSA and BNA-HSA complexes was also investigated. All pH measurements
were validated with a Fisher Scientific AB15 pH meter.

2.1.5 TFE and BNA Enantiomer Titration of TN Breast Cancer Cells
Triple negative breast cancer cells were exposed to a known concentration of TFE and BNA
enantiomers for a period of 24 hours. Prior to chemical treatment, the cells were washed with 2mL of
phosphate buffered saline (PBS). The PBS was removed and 2mL of fresh media was added. Treated cell
were then allowed to incubate for 24 hours at 37°C and 5% CO2. Treated cells were photographed at 10x
and 20x magnification to observe any physical characteristics of cell death.

2.2 Instrumentation
2.2.1 Fluorescence Spectroscopy Studies
The fluorescence studies of TFE-HSA and BNA-HSA complexes were carried out on a
JASCO FP-8500 spectrofluorometer equipped with temperature control using a 1 cm quartz cell.
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The light source is a 150W xenon lamp with emission and excitation slit width of 2.5nm with a
scan speed of 200nm/min. The emission spectra was recorded from 285nm to 551nm while the
excitation was ran at 280nm. Fluorescence data was collected for HSA in the absence and presence
of various concentrations of R- and S-TFE.

2.2.2 Fluorescence Anisotropy Studies
The fluorescence anisotropy measurements studies were carried out on the same JASCO
FP-8500 spectrofluorometer with an automated polarizer accessory. Parallel and perpendicular
emission components were measured in L-format by excitation at 295 nm from a 150-W xenon
lamp. With each anisotropy measurement the parallel and perpendicular intensity of the
background buffer solution was subtracted from the measured values of the sample. Anisotropy
was measured three times at each titration point and the resulting anisotropy values were
averaged.

2.2.3 UV Absorption Studies
The UV spectra was recorded with a Shimadzu UV-3600 NIR Spectrophotometer.
Wavelength range began at 190 to 550nm with a fast scan speed. Sampling interval were set to
5nm while measuring in absorbance and slit width set to 2.0nm.

2.2.4 Fourier Transform Infrared Spectroscopy Studies
FTIR studies were obtained by a Shimadzu IR Affinity-1 FTIR spectrophotometer. All
samples were obtained ATR accessory under % transmittance with 100 scans. Wavenumber range
from 700cm-1 to 1400cm-1.
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CHAPTER 3
RESULTS
3.1 UV Spectra of HSA

Figure 15. Uv-Vis Absorbance spectra of HSA
The UV-Vis absorbance of HSA was taken to obtain an approximate concentration of the
protein. Literature places the λ max of HSA at 280nm with a ε coefficient of 38553 Lmol-1cm-1.
Figure 15 shows the UV-Vis absorption spectra of 2.7x10-5M of HSA in 30mM MOPS buffer at
pH 7.4. The effects of temperature on the absorption spectra of HSA is shown below in figure
15. Increasing temperatures lead to a decrease in the intrinsic absorption of HSA due to the
denaturing of the proteins tertiary structure.
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Figure 16. Effects of Temperataure on HSA Absorbance
3.2 Effects of Temperature on HSA Fluorescence
HSA has a major binding site that involves the lone tryptophan residue (Trp-214) which
attributes to its intrinsic maximum fluorescence at 335nm. Tryptophan emission was monitored
over five increasing temperatures 25, 37, 45, 55 and 65° Celsius.

Figure *17. Influence of temperature on Fluorescence Spectra of HSA
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Similar to its absorbance the fluorescence intensity of HSA decreased with the increase of
temperature.

3.3 FTIR Spectra of HSA and R- and S- TFE

N-H

Amide 1

Amide 2

Aromatic

Figure *18. FTIR spectra of pure HSA, R- and S-TFE
As stated previously, HSA is a large complex protein so it is expected to see amide peaks
at approximately 1645 and 1521cm-1 corresponding to the C= O stretching and N-H bending
respectively. Also seen is a broad peak at 3327cm-1 attributed by overlaid N-H stretching and OH stretching. The spectra of R- and S-TFE both exhibit peaks around 3300 cm-1 from O-H
stretching and aromatic C=C bending around 1600-1500 cm-1. The spectra’s are expected to look
identical due to the fact that enantiomers exhibit the same physical and spectral properties.
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3.4 FTIR Spectra of HSA and R- and S- BNA

Aromatic

Figure 17. FTIR Spectra of pure HSA, R- and S- BNA
As stated previously, HSA is a large complex protein so it is expected to see amide peaks
at approximately 1645 and 1521cm-1 corresponding to the C= O stretching and N-H bending
respectively. Also seen is a broad peak at 3327cm-1 attributed by overlaid N-H stretching and OH stretching. The spectra of R-and S-BNA exhibits two intense peaks at 3381 and 3473cm-1 due
to its amine groups present as well as aromatic C=C bending around 1600-1500 cm-1. The
spectra’s are expected to look identical due to the fact that enantiomers exhibit the same physical
and spectral properties.
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3.5 Fluorescence Spectra of Enantiomers of HSA-TFE
The fluorescence studies of HSA emission was performed at 25 37, 45, and 55 °C to later
examine the thermodynamic properties associated with the TFE-HSA complexes. HSA
concentration was fixed at 2.7x 10-6 M while varying the concentrations of R- and S-TFE from
2.0x10-7 to 2.0x10-5µM.

Figure 18. Fluorescence Spectra of R-TFE-HSA solution at 37 °C with concentrations ranging
from 2.0x10-6 to 7.0x10-6M at pH 7.4 Emission spectra= 285-551nm, Excitation= 280nm
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Figure 19. Fluorescence Spectra of S-TFE-HSA solution at 37 °C with concentrations ranging
from 2.0x10-6 to 7.0x10-6M at pH 7.4 Emission spectra= 285-551nm, Excitation= 280nm

In the case of both enantiomers the addition of TFE leads to a decrease in fluorescence
intensity of HSA at the λ max, indicating R- and S-TFE as quenching agents. We can also
conclude that the increase of TFE concentration simultaneously decreases the fluorescence
intensity while a slight blue shift is observed after reaching higher temperatures (a characteristic
common to that of static quenching). Another region of interest is the emission at a longer
wavelength that corresponds to TFE emission with a λ max of 417nm.Compared with tryptophan
residue in HSA, TFE is more conjugated and is expected to emit at a longer wavelength. Increase
in TFE concentration in HSA samples resulted in increased fluorescence intensity at the TFE
region. In contrast the formation of TFE-HSA complex reduces the fluorescence intensity of TFE
and is only further reduced by increasing temperatures. Additionally noted is the presence of an
isobestic point around 338nm both R-and S-TFE. The profiles of R- and S-TFE look identical so
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an overlay of the emission of R- and S-TFE is plotted against concentration to obtain a more
accurate observation and differences in emission properties of R- and S-TFE complexes.

Figure 20. Overlaid emission of R-TFE-HSA and S-TFE-HSA Complexes

Figure 23 shows that despite identical concentrations and being exposed to the exact
same parameters there is still clear discrimination between the two enantiomers. The S
configuration leads to a larger florescence decrease than its R enantiomer.

3.6 Fluorescence Spectra of Enantiomers of HSA-BNA-Complexes
The fluorescence studies using BNA as the chiral compound were performed identical to TFE
complex samples. Samples were ran at 25 37, 45, and 55 °C with HSA concentration fixed at 2.7x 106

M while varying the concentrations of R- and S-BNA from 2.0x10-7 to 2.0x10-5µM.
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Figure 21. Fluorescence Spectra of R-BNA-HSA solution at 37 °C with concentrations ranging
from 2.0x10-6 to 7.0x10-6M at pH 7.4 Emission spectra= 285-551nm, Excitation=280nm

Figure 22. Fluorescence Spectra of S-BNA-HSA solution at 37 °C with concentrations ranging
from 2.0x10-6 to 7.0x10-6M at pH 7.4 Emission spectra= 285-551nm, Excitation= 280nm
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Similar to that of HSA-TFE complexes the addition of both enantiomers of BNA leads to
the decrease in fluorescence intensity of HSA emission resulting in BNA also being a
quenching agent. We can also note that the increase of BNA concentration simultaneously
decreases the fluorescence intensity of HSA. Another region of interest is that of the BNA
region. Additionally noted is the presence of an isobestic point around 373nm both R-and SBNA.
We can also conclude that the increase of BNA concentration simultaneously decreases
the fluorescence intensity. However unlike TFE, BNA showed no signs of spectral shift with
increasing temperatures or concentration. The profiles of R- and S-TFE look identical so an
overlay of the emission of R- and S-TFE is plotted against concentration to obtain a more
accurate observation.

Figure 23. Overlaid emission of R- and S-BNA Complexes
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Figure 26 shows that despite identical concentrations and being exposed to the exact
same parameters there is still clear discrimination between the two enantiomers. The S
configuration leads to a larger florescence decrease than its R enantiomer.

3.7 Determination of Binding Constant and Stoichiometry of R- and S-TFE-HSA
Complexes
When smaller molecules bind to large complex proteins at equivalent sites the
equilibrium between the two can be evaluated using a modified Stern-Volmer equation shown
below.

log (

𝐹0 −𝐹
𝐹

) = log K + nlog [TFE] ...................................................................................... Equation 9

Where K is the binding association constant to a particular site and n is molar ratio of
TFE to HSA. F0 and F represent the fluorescent intensity before and after the addition of TFE
respectively. This linear equation can be utilized by plotting the log [TFE] against the log of the
change in fluorescence intensity.
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Figure 24. Stern Volmer plot of R-TFE-HSA Complexes

Figure 25. Stern Volmer plot of S-TFE-HSA Complexes
From the slope and intercept of figures 20 and 21 the binding constant and stoichiometric
ratios are shown in the table 2 below.
Table 2. Binding & Stoichiometric Parameters of HSA-R and S-TFE
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Based on our calculations the binding of TFE to HSA takes place at one site. However
the binding constants differ significantly. This only further validates the importance chirality
plays in protein-drug selection. At physiological temperatures the affinity of R-TFE to HSA is
thirty-seven times higher than its S enantiomer while increasing temperatures only enhance the
ratio.

3.8 Determination of Binding Constant and Stoichiometry of R- and S-BNA-HSA
Complexes
Determination of binding constant and stoichiometry of R- and S-BNA-HSA was also
evaluated by equation 9. This linear equation can be utilized by plotting the log [BNA] against
the log of the change in fluorescence intensity.
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Figure 26. Stern Volmer plot of R-BNA-HSA Complexes

Figure 27. Stern Volmer plot of S-BNA-HSA Complexes
From the slope and intercept of figures 20 and 21 the binding constant and stoichiometric
ratios are shown in the table 2 below.
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Table 3.
Binding & Stoichiometric Parameters of HSA-R and S-BNA

Based on our calculations the binding of BNA to HSA takes place at one site. Likewise to
TFE the binding constants differ significantly. At physiological temperatures the affinity of RBNA to HSA is one hundred and thirty times higher than its S enantiomer while increasing
temperatures only enhance the ratio.

3.9 Steady State Anisotropy Measurements
Steady state anisotropy measurements were done to further explore chiral discrimination
by monitoring its change in rotational diffusion.
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BSA R-TFE vs S-TFE
AVERAGE
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Figure 28. Overlaid Anisotropy values Spectra of R- and S-TFE-HSA Complexes
Sample preparation was similar to steady state fluorescence experiments above and the
experiment was ran in triplicates. 27µM bovine serum albumin (BSA) in buffer solution was
subject to anisotropy experiments to serve as preliminary experiments. The anisotropy values of
BSA is initially increased upon binding to R-TFE while initial decreasing is observed in S-TFE
complexes. Although the values show a type of erratic pattern you can still observe the
enantiomers are always opposite to one another. As TFE concentration approaches that of BSA
the anisotropy values becomes approximately back to that of its unbound state. In these
experiments the change in anisotropy values correspond to the binding of the drug to the protein
and at the drugs highest concentration (20µM) the anisotropy exhibits values similar to its
unbound state indicative of no interaction between the drug and the protein.

3.10 Thermodynamic Properties of Enantiomer of TFE-HSA Complexes
Small molecules can bind independently to large proteins at equivalent sites and they can
do so by four possible binding modes: hydrogen bonds, van der Walls forces, ionic interactions,
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or hydrophobic interactions. Thermodynamic parameters are essential for determining the
driving force of chemical reactions thus this study was performed at four different temperatures
to better understand the driving force associated with the binding of TFE to HSA.
The Van’t Hoff equation (equation 12) and the Gibbs free energy equation (equation 11)
shown below can be applied to aid in determining these parameters.38 If the reaction equation is
at equilibrium the following relationship can be said.
∆G = -RT ln K ................................................................................................................ Equation 10

Where ∆G is the Gibbs free energy, R is the gas constant and K is the binding constants
calculated previously at a specific temperature (T). Rearranging the equation to solve for the
natural log and replacing ∆G with its equality in equation 11, we arrive to the linear Van’t Hoff
equation.
∆G=∆H-T∆S .................................................................................................................. Equation 11

ln K=

−∆𝐻
𝑅𝑇

+

∆𝑆
𝑅

.............................................................................................................. Equation 12

Where K is the binding constant discovered earlier at the temperature (T) indicated and R
is the gas constant. A plot of the inverse temperature against the ln K is produced and the slope
and intercept are used to calculate enthalpy (ΔH) and entropy (ΔS) associated with the complex
formation of R- and S-TFE-HSA complexes at a specific temperature. The Gibbs free energy can
then be estimated by using equation 11.39
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Figure 29. Van’t Hoff plot of R-TFE-HSA Complexes

Figure 30. Van’t Hoff plot of S-TFE-HSA Complexes
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Table 4.
Thermodynamic parameters of R- and S-TFE-HSA Complexes

The negative values of ∆G shown for R- and S-TFE reveals that the interactions between
both enantiomers of TFE and HSA are in fact spontaneous. Ross and Subramanian40 have
constructed a graph that correlates the sign and magnitude of the thermodynamic parameters to
the various types of interactions that can take place in protein-ligand binding.
Table 5.
Expected signs of controbutions to ∆H and ∆S 40

Process

∆H

∆S

Hydrophobic

+

+

Van der Walls

-

-

H-Bonding

-

-

Ionic

Slight + or -

+
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In the case of HSA binding to R- and S-TFE the positive ∆H and ∆S values correspond to a high
possibility of hydrophobic interactions.

3.11 Thermodynamic Properties of Enantiomer of BNA-HSA Complexes
Similar to that of TFE-HSA diastereomic complexes, the relationship between equations
10 and 11 were used to obtain the linear Van’t Hoff equation and from the slope and intercept are
the values found in table 6.

Figure 31. Van’t Hoff plot of R-BNA-HSA Complexes
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Figure 32. Van’t Hoff plot of S-BNA-HSA Complexes
Table 6.
Thermodynamic parameters of R- and S-BNA-HSA Complexes

The negative values of ∆G shown for S-BNA and positive values of R-BNA reveal that the
interactions between one enantiomer is favored while the other is not.
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3.12 Enantiomeric Cytotoxicity on Triple Negative Breast Cancer Cells
Preliminary cell cytotoxicity studies were conducted on triple negative breast cancer cells to
observe any discriminatory differences by enantiomers of TFE and BNA. Cell viability was taken 24
hours after exposure to known concentrations of both TFE and BNA enantiomers. Figures 36 through 42
is the microscopic view of the effects of TFE and BNA enantiomers on triple negative breast cancer cells
at 10x magnification after 24 hour exposure.

Figure 33. Pretreatmnent 10x

Figure 35. Methanol Control 10x

Figure 34. No Treatment 10x
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Figure 36. S-BNA Treatment 10x

Figure 37. R-BNA Treatmeant 10x

Figure 38. S-TFE Treatment 10x

Figure 39. R-TFE Treatment 10x
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CHAPTER 4
DISCUSSION
4.1 Determination of Binding Constant and Stoichiometry of Enantiomers of HSA-TFE
Referring to Table 2, clear chiral discrimination is observed during the binding of R-TFE
to HSA and S-TFE to HSA. Both enantiomers exhibit the same stoichiometric ratio to the
protein. However despite identical chemical composition of the compounds, HSA is still able to
discriminate between the two enantiomers. Both enantiomers exhibit stronger affinity with
increasing temperature even though R-TFE complexes show an affinity eight times higher than
S-TFE.
4.2 Determination of Binding Constant and Stoichiometry Enantiomers of HSA-BNA
Despite differences in the structure and chemical composition of TFE and BNA, the
binding interactions of BNA enantiomers to HSA further proves chiral discrimination. The
binding of R- and S-TFE to HSA has one binding site. However, the spatial arrangement of the
enantiomers is allowing them to interact differently with the protein. In contrast to TFE
diastereomer complexes, increasing temperatures decrease binding affinity for the S
configuration.

4.3 Thermodynamic Properties of Enantiomer of HSA-TFE Complexes
Referencing Table 4, at physiological temperatures the interaction between both R- and
S-TFE is determined favorable by its ∆G value. The enthalpy change associated with the R
enantiomer is almost three times higher than its S enantiomer. This could be a result of higher
binding affinity. In both cases the disorder in the system is miniscule in comparison to its
enthalpy value, however the ∆S values differ significantly between the two enantiomers. The ∆S
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is two times higher in R-TFE than in S-TFE. Based on the signs and magnitudes of the calculated
thermodynamic parameters the binding interactions are largely contributed by hydrophobic
interactions.40 These interaction could be possible by potential unfolding of the protein to allow
TFE to enter into a hydrophobic region on the protein. However, other factors including
hydrogen bonding and electron transfer may also facilitate the TFE-HSA complex formation.
Some principle binding sites on HSA are noted to have large hydrophobic cavities however the
literature suggest typical ligands for this site are bulky heterocyclic molecules and the
interactions to be electrostatic. Further research must be conducted to obtain an approximate
binding mechanism.

4.4 Thermodynamic Properties of Enantiomer of HSA-BNA Complexes
Referencing Table 6, at physiological temperatures the interaction between S-BNA is
favorable however its R-enantiomer is not. These values raise concern when examining the
higher binding constant shown for the R-enantiomer. Another interesting observation is the
different signs for the disorder and enthalpy in the system of R- and S-TFE. A negative value for
∆S indicates the disorder involved in the interaction of S-BNA and HSA is lowered upon
binding. However this R-BNA-HSA complex also exhibits and negative H values indicating that
the reaction is exothermic and possibly driven by enthalpy. The negative values for both ∆S and
∆H indicate the major mode of binding is due to hydrogen bonds and van der Walls forces. This
BNA complex has four hydrogen atoms on its exterior that can assist in hydrogen bonding to and
van der Wall forces to the positively charges side chains of the amino acids in the protein.
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4.5 Cell Viability and Cytotoxicity Studies
Preliminary studies at concentration 3.0X10-5M, show clear morphology effects in the
presence of TFE and BNA enantiomers. From the differences of S-BNA and R-BNA in Figures
39 and 40 respectively, the R-BNA shows a qualitative difference in cell viability. In contrast to
BNA enantiomers S-TFE shows the qualitative difference in cell viability. Something of
immediate interest was the relationship between the K values and the observations during cell
viability. Our BNA enantiomers which showed higher binding constants where able to penetrate
the cells more than the TFE enantiomers. Cell viability experiments are still currently being
optimized for each compound.

55

CHAPTER 5
CONCLUSION
This work successfully utilized Fluorescence, UV-visible and Fourier transform infrared
spectroscopy to shows the chiral discrimination between two different chiral environmental
pollutants, S (-), R (+) 1- (9-anthryl) - 2, 2, 2- triflouroethanol (TFE) and (R)-(+), (S)-(-)-1,1′binaphthyl-2,2′-diamine (BNA) in solution with human serum albumin as the chiral selector.
This study shows that both compounds act as a quencher of intrinsic HSA fluorescence and do so
by static quenching. From the quenching studies we were able to determine the binding
constants, stoichiometry and, thermodynamic parameters of binding to HSA. This work also
began to explore the mobility and cytotoxicity of our compounds.

56

REFERENCES
1. Nguyen, L. A.; He, H.; Pham-Huy, C., Chiral Drugs: An Overview. International Journal
of Biomedical Science : IJBS 2006, 2 (2), 85-100.
2. Gal, J., Molecular chirality: language, history, and significance. Topics in current
chemistry 2013, 340, 1-20.
3. Blackmond, D. G., The Origin of Biological Homochirality. Cold Spring Harbor
Perspectives in Biology 2010, 2 (5), a002147.
4. McConathy, J.; Owens, M. J., Stereochemistry in Drug Action. Primary Care Companion
to The Journal of Clinical Psychiatry 2003, 5 (2), 70-73.
5. Hutt, A. J.; O'Grady, J., Drug chirality: a consideration of the significance of the
stereochemistry of antimicrobial agents. The Journal of antimicrobial chemotherapy
1996, 37 (1), 7-32.
6. Chuang, V. T.; Otagiri, M., Stereoselective binding of human serum albumin. Chirality
2006, 18 (3), 159-66.
7. Ali, I.; A. Wani, W.; Saleem, K.; Haque, A., Thalidomide: A Banned Drug Resurged into
Future Anticancer Drug. Current Drug Therapy 2012, 7 (1), 13-23.
8. Shen, Q.; Wang, L.; Zhou, H.; Jiang, H. D.; Yu, L. S.; Zeng, S., Stereoselective binding
of chiral drugs to plasma proteins. Acta pharmacologica Sinica 2013, 34 (8), 998-1006.
9. Fasano, M.; Curry, S.; Terreno, E.; Galliano, M.; Fanali, G.; Narciso, P.; Notari, S.;
Ascenzi, P., The extraordinary ligand binding properties of human serum albumin.
IUBMB life 2005, 57 (12), 787-96.
10. Meloun, B.; Morávek, L.; Kostka, V., Complete amino acid sequence of human serum
albumin. FEBS Letters 1975, 58 (1–2), 134-137.

57

11. Petitpas, I.; Bhattacharya, A. A.; Twine, S.; East, M.; Curry, S., Crystal structure analysis
of warfarin binding to human serum albumin: anatomy of drug site I. The Journal of
biological chemistry 2001, 276 (25), 22804-9.
12. Ali, I.; Aboul-Enein, H. Y., Chiral Pollutants: Sources and Distribution. In Chiral
Pollutants: Distribution, Toxicity and Analysis by Chromatography and Capillary
Electrophoresis, John Wiley & Sons, Ltd: 2004; pp 37-74.
13. Eisler, R.; Fish, U. S.; Wildlife; Fish, U. S.; Wildlife, S.; Patuxent Wildlife Research, C.,
Polycyclic aromatic hydrocarbon hazards to fish, wildlife, and invertebrates: a synoptic
review. Fish and Wildlife Service, U.S. Dept. of the Interior: Laurel, MD, 1987; p viii, p
81.
14. Ali, I.; Aboul-Enein, H. Y., Chiral Pollutants: Biotransformation, Biodegradation and
Metabolism. In Chiral Pollutants: Distribution, Toxicity and Analysis by
Chromatography and Capillary Electrophoresis, John Wiley & Sons, Ltd: 2004; pp 75108.
15. Ross, P. D.; Subramanian, S., Thermodynamics of protein association reactions: forces
contributing to stability. Biochemistry 1981, 20 (11), 3096-3102.
16. Yue, Y.; Chen, X.; Qin, J.; Yao, X., Spectroscopic investigation on the binding of
antineoplastic drug oxaliplatin to human serum albumin and molecular modeling.
Colloids and Surfaces B: Biointerfaces 2009, 69 (1), 51-57.
17. Sudhakar, A., History of Cancer, Ancient and Modern Treatment Methods. Journal of
cancer science & therapy 2009, 1 (2), 1-4.

58

18. Wan, X.; Zheng, X.; Pang, X.; Zhang, Z.; Jing, T.; Xu, W.; Zhang, Q., The potential use
of lapatinib-loaded human serum albumin nanoparticles in the treatment of triplenegative breast cancer. International Journal of Pharmaceutics 2015, 484 (1–2), 16-28.
19. American Cnancer Society. Cancer: Breast Cancer.
http://www.cancer.org/cancer/breastcancer/index (Accessed Feb. 26, 2015).
20. Acuña, A. U.; Amat-Guerri, F.; Morcillo, P.; Liras, M.; Rodríguez, B., Structure and
Formation of the Fluorescent Compound of Lignum nephriticum. Organic Letters 2009,
11 (14), 3020-3023.
21. O'Haver, T. C., Development of luminescence spectrometry as an analytical tool. Journal
of Chemical Education 1978, 55 (7), 423.
22. Valeur, B.; Berberan-Santos, M. r. N., A Brief History of Fluorescence and
Phosphorescence before the Emergence of Quantum Theory. Journal of Chemical
Education 2011, 88 (6), 731-738.
23. Sauer, M.; Hofkens, J.; Enderlein, J., Basic Principles of Fluorescence Spectroscopy. In
Handbook of Fluorescence Spectroscopy and Imaging, Wiley-VCH Verlag GmbH & Co.
KGaA: 2011; pp 1-30.
24. Möller, M.; Denicola, A., Protein tryptophan accessibility studied by fluorescence
quenching. Biochemistry and Molecular Biology Education 2002, 30 (3), 175-178.
25. Calhoun, D. B.; Vanderkooi, J. M.; Holtom, G. R.; Englander, S. W., Protein
fluorescence quenching by small molecules: protein penetration versus solvent exposure.
Proteins 1986, 1 (2), 109-15.
26. Harvey, E. N., A history of luminescence from the earliest times until 1900. American
Philosophical Society: Philadelphia, 1957.

59

27. Tan, M.; Liang, W.; Luo, X.; Gu, Y., Fluorescence Spectroscopy Study on the Interaction
between Evodiamine and Bovine Serum Albumin. Journal of Chemistry 2013, 2013, 6.
28. Bian, Q.; Liu, J.; Tian, J.; Hu, Z., Binding of genistein to human serum albumin
demonstrated using tryptophan fluorescence quenching. International journal of
biological macromolecules 2004, 34 (5), 333-7.
29. Patel, S.; Datta, A., Steady state and time-resolved fluorescence investigation of the
specific binding of two chlorin derivatives with human serum albumin. The journal of
physical chemistry. B 2007, 111 (35), 10557-62.
30. Yang, G.-D.; Li, C.; Zeng, A.-G.; Zhao, Y.; Yang, R.; Bian, X.-L., Fluorescence
spectroscopy of osthole binding to human serum albumin. Journal of Pharmaceutical
Analysis 2013, 3 (3), 200-204.
31. Bioanalytical Applications of Fluorescence Spectroscopy. Analytical chemistry 1988, 60
(18), 1031A-1039A.
32. Mann, T. L.; Krull, U. J., Fluorescence polarization spectroscopy in protein analysis.
Analyst 2003, 128 (4), 313-317.
33. Ingersoll, C. M.; Strollo, C. M., Steady-State Fluorescence Anisotropy To Investigate
Flavonoids Binding to Proteins. Journal of Chemical Education 2007, 84 (8), 1313.
34. Cheow, L. F.; Viswanathan, R.; Chin, C. S.; Jennifer, N.; Jones, R. C.; Guccione, E.;
Quake, S. R.; Burkholder, W. F., Multiplexed analysis of protein-ligand interactions by
fluorescence anisotropy in a microfluidic platform. Analytical chemistry 2014, 86 (19),
9901-8.
35. Fluorescence Anisotropy. In Principles of Fluorescence Spectroscopy, Lakowicz, J., Ed.
Springer US: 2006; pp 353-382.

60

36. Kimaru, I. W.; Xu, Y.; McCarroll, M. E., Characterization of chiral interactions using
fluorescence anisotropy. Analytical chemistry 2006, 78 (24), 8485-90.
37. Ameloot, M.; vandeVen, M.; Acuña, A. U.; Valeur, B., Fluorescence anisotropy
measurements in solution: Methods and reference materials (IUPAC Technical Report).
In Pure and Applied Chemistry, 2013; Vol. 85, p 589.
38. Vlachos, N.; Skopelitis, Y.; Psaroudaki, M.; Konstantinidou, V.; Chatzilazarou, A.;
Tegou, E., Applications of Fourier transform-infrared spectroscopy to edible oils.
Analytica Chimica Acta 2006, 573–574 (0), 459-465.
39. Barth, A., Infrared spectroscopy of proteins. Biochimica et Biophysica Acta (BBA) Bioenergetics 2007, 1767 (9), 1073-1101.
40. Kong, J.; Yu, S., Fourier transform infrared spectroscopic analysis of protein secondary
structures. Acta biochimica et biophysica Sinica 2007, 39 (8), 549-59.

